{"url_path":"/sec/abbv/8-k/2026-07-06/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-06","source_url":"https://www.sec.gov/Archives/edgar/data/1551152/0001551152-26-000021-index.html","accession_number":"0001551152-26-000021","cik":"0001551152","ticker":"ABBV","issuer_name":"AbbVie Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1551152/0001551152-26-000021-index.html","primary_entity_key":"0001551152","primary_entity_name":"AbbVie Inc."},"word_count":88,"has_tables":true,"body_markdown":"Item 9.01 Financial Statements and Exhibits\n\n(d) Exhibits\n\nExhibit No. Exhibit\n\n[99.1](abbv-20260630nonxgaapxex991.htm)\n \n[Guidance including the impact of acquired IPR&D and milestones expense](abbv-20260630nonxgaapxex991.htm).\n\n104The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).\n\nSIGNATURE\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n  ABBVIE INC.\n\n   \n\nDate:July 6, 2026By:/s/ Scott T. Reents\n\n  Scott T. Reents\n\n  Executive Vice President,\n\n  Chief Financial Officer"}